Regulatory Strategy & Development Planning

Making the most of every piece of the regulatory puzzle.

When it comes to clinical development, we’re dedicated to getting every moment right. And we have the people to get you there. The seasoned advisors on our Regulatory Consulting Services team have decades of experience helping teams interpret new and existing guidance throughout the process – and throughout the world. In fact, many of them are former FDA, EMA, and NMPA regulators themselves. 

Our services include:

  • Regulatory Strategy: Global product development strategy, clinical, non-clinical, CMC, and regulatory gap analysis, due-diligence, product and indication prioritization, regulatory pathway optimization and acceleration strategy, global labelling (CCDS updates), marketing authorization applications (US, EU, China, Japan, Canada, and emerging markets-ROW), submission planning (eCTD), patient-focused development
  • Health Authority Meetings: Preparation support, briefing documents, rehearsals, meeting attendance, and health authority liaison
  • Quality system inspection: Strategy and inspection readiness
  • Submission support: Storyboarding/key messaging, core submission preparation and authoring, original application publishing with lifecycle maintenance, lifecycle publishing, global dossier management, RTQs, and CTA core dossier development
  • Stakeholder Management: Drug safety, technical operations, medical and commercial stakeholder management
  • Mergers and Acquisitions: Planning, submission authoring, dossier collection, and stakeholder management
WHITE PAPER / COMMERCIALIZATION

HOW CAN THE BIOSIMILAR CONCEPT BE APPLIED TO MORE COMPLEX PROTEINS SUCH AS MONOCLONALS?

An overview of the biosimilar concept, focused on the European Union's approval process for "similar biological medicinal products."

Learn More

Regulatory services brochure

Regulatory, Development and Commercial 
Expertise. Operational Excellence. One Source.

View Now

What To Consider When Mapping Your Strategy For Submitting An Application To The National Drug Administration of China

Read Now

New post-market Surveillance requirements (PMS) for medical device manufacturers

Read Now

FDA Releases Draft Guidance on CMC for Gene Therapies

Read Now

Will You “Lose” On The FDAs 15 Day 483 Diet Plan?

Read Now

FDA Releases a Biopharmaceutical Naming Update

Read Now

We are always available for a conversation.

*